Back

Replimune investors file class action over RP1 FDA resubmission disclosures

Verifying
  • Investors filed a securities class action against Replimune Group over RP1 resubmission disclosures.
  • Replimune shares fell about 84%, or $9.03 per share, across April 10 and April 13.
  • Investors have until October 5, 2026, to seek lead plaintiff appointment in Massachusetts federal court.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.